Autopsy report · NCT04402788
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Cause of deathOther
“Scheduled Interim Monitoring”
Life of this trial
- Registered 8 months before it started.
- Suspended: paused, and may or may not restart.
- 138 participants planned (an estimate, not an actual count).
Vital statistics
- Status
- Suspended
- Phase
- Phase 2, Phase 3
- Sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Conditions
- Extensive Stage Lung Small Cell Carcinoma
- Interventions
- Atezolizumab; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Positron Emission Tomography; Radiation Therapy
- Participants
- 138 (planned, not actual)
- Sites
- 411
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.